Nortriptyline

Pamelor, Aventyl

Antidepressant • Tricyclic antidepressant (TCA)

Premium

NTIQT RiskSerotoninergicCNS Depressant

Half-life

18-44 hours

Protein Binding

93-95%

Metabolized By

CYP2D6

External

Drugs.com

Boxed warning

Suicidality in children, adolescents, and young adults

Clinical alerts

Boxed warning

1 boxed warning

Narrow therapeutic index

Small dose changes can cause toxicity or loss of effect

QT prolongation

Avoid combining with other QT-prolonging agents; check electrolytes

Serotonergic

Serotonin syndrome risk when combined with other serotonergic drugs

Anticholinergic

Adds to anticholinergic burden, particularly in older patients

CNS depressant

Additive sedation with other CNS depressants and alcohol

Mechanism of action

Inhibits reuptake of norepinephrine and serotonin; also blocks muscarinic, histamine, and alpha-1 receptors

Recorded indications

From the drug index — may include conditions studied rather than approved indications

·Lumbosacral Radiculopathy
·Vestibulodynia
·Temporomandibular Disorder
·Fibromyalgia Syndrome
·Irritable Bowel Syndrome

Interactions

No curated interaction pairs are recorded for Nortriptyline. This is not a statement that none exist — check a full interaction reference before combining.

Common adverse effects

Dry mouth
Constipation
Urinary retention
Sedation
Weight gain
Orthostatic hypotension

Food, alcohol & herbal

Alcohol · major

Severe CNS depression; impaired motor skills

Herbal

St. John's Wort (major) — Risk of serotonin syndrome; may also reduce TCA levels

Pharmacokinetics

Half-life: 18-44 hours
Protein binding: 93-95%
Metabolised by: CYP2D6

Pregnancy & lactation

Not recorded for Nortriptyline. Absence here means this database does not hold a category — not that the drug is safe in pregnancy or breastfeeding.

Sources

Assembled from: drug index, curated drug database.

Not a substitute for clinical judgement

Nortriptyline

Pamelor, Aventyl

Antidepressant • Tricyclic antidepressant (TCA)

Premium

NTIQT RiskSerotoninergicCNS Depressant

Half-life

18-44 hours

Protein Binding

93-95%

Metabolized By

CYP2D6

External

Drugs.com

Boxed warning

Suicidality in children, adolescents, and young adults

Clinical alerts

Boxed warning

1 boxed warning

Narrow therapeutic index

Small dose changes can cause toxicity or loss of effect

QT prolongation

Avoid combining with other QT-prolonging agents; check electrolytes

Serotonergic

Serotonin syndrome risk when combined with other serotonergic drugs

Anticholinergic

Adds to anticholinergic burden, particularly in older patients

CNS depressant

Additive sedation with other CNS depressants and alcohol

Mechanism of action

Inhibits reuptake of norepinephrine and serotonin; also blocks muscarinic, histamine, and alpha-1 receptors

Recorded indications

From the drug index — may include conditions studied rather than approved indications

·Lumbosacral Radiculopathy
·Vestibulodynia
·Temporomandibular Disorder
·Fibromyalgia Syndrome
·Irritable Bowel Syndrome

Interactions

No curated interaction pairs are recorded for Nortriptyline. This is not a statement that none exist — check a full interaction reference before combining.

Common adverse effects

Dry mouth
Constipation
Urinary retention
Sedation
Weight gain
Orthostatic hypotension

Food, alcohol & herbal

Alcohol · major

Severe CNS depression; impaired motor skills

Herbal

St. John's Wort (major) — Risk of serotonin syndrome; may also reduce TCA levels

Pharmacokinetics

Half-life: 18-44 hours
Protein binding: 93-95%
Metabolised by: CYP2D6

Pregnancy & lactation

Not recorded for Nortriptyline. Absence here means this database does not hold a category — not that the drug is safe in pregnancy or breastfeeding.

Sources

Assembled from: drug index, curated drug database.

Not a substitute for clinical judgement

Nortriptyline Drug Profile | PharmaGraphX